Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
Treatment of Acute Pericarditis With Anakinra
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 5
- Registration Number
- NCT03224585
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 12
- Registration Number
- NCT03200782
- Locations
- 🇨🇭
University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism, Basel, Switzerland
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 22
- Registration Number
- NCT03182426
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Anti-Cytokine Therapy for Hemodialysis InflammatION
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 80
- Registration Number
- NCT03141983
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸University of Washington Kidney Research Institute, Seattle, Washington, United States
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Virginia Commonwealth University
- Registration Number
- NCT03062176
Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 7
- Registration Number
- NCT03057028
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis
- Conditions
- Interventions
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 112
- Registration Number
- NCT02929251
- Locations
- 🇫🇷
Hopital Pellegrin, Bordeaux, France
🇫🇷Hopital Saint André - Médecine interne, Bordeaux, France
🇫🇷HCL - Hôpital de la Croix Rousse - Ophtalmologie, Lyon, France
Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT02916355
- Locations
- 🇨🇭
University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism, Basel, Switzerland
Kineret in the Treatment of Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 30
- Registration Number
- NCT02915094
- Locations
- 🇩🇪
Swedish Orphan Biovitrum Investigational Site, Freiburg, Germany
Giant Cell Arteritis and Anakinra Trial
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 70
- Registration Number
- NCT02902731
- Locations
- 🇫🇷
Pr Aouba, Caen, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.